Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, Cuk K, Riethdorf S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Surowy H, Burwinkel B. Madhavan D, et al. Among authors: wallwiener m. Breast Cancer Res Treat. 2014 Jul;146(1):163-74. doi: 10.1007/s10549-014-2946-2. Epub 2014 May 17. Breast Cancer Res Treat. 2014. PMID: 24838941
Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels.
Wallwiener CW, Wallwiener M, Kurth RR, Röhm C, Neubauer H, Banys MJ, Staebler A, Schönfisch B, Meuer SC, Giese T, Fehm TN. Wallwiener CW, et al. Among authors: wallwiener m. Breast Cancer Res Treat. 2011 Dec;130(3):833-44. doi: 10.1007/s10549-011-1710-0. Epub 2011 Aug 21. Breast Cancer Res Treat. 2011. PMID: 21858660
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, Lenz F, Fricke HC, Solomayer E, Fersis N, Schmidt M, Wallwiener M, Schneeweiss A, Sohn C. Eichbaum M, et al. Among authors: wallwiener m. BMC Cancer. 2011 Oct 20;11:453. doi: 10.1186/1471-2407-11-453. BMC Cancer. 2011. PMID: 22014006 Free PMC article. Clinical Trial.
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B. Madhavan D, et al. Among authors: wallwiener m. Clin Cancer Res. 2012 Nov 1;18(21):5972-82. doi: 10.1158/1078-0432.CCR-12-1407. Epub 2012 Sep 4. Clin Cancer Res. 2012. PMID: 22952344
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN. Wallwiener M, et al. Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28. Breast Cancer Res Treat. 2013. PMID: 23271327 Clinical Trial.
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Röhm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, Walter C, Neubauer H, Wallwiener D, Fehm T. Hartkopf AD, et al. Among authors: wallwiener d, wallwiener m. Breast Cancer Res Treat. 2013 Apr;138(2):509-17. doi: 10.1007/s10549-013-2470-9. Epub 2013 Mar 15. Breast Cancer Res Treat. 2013. PMID: 23494674
262 results